FDA approves Dupixent as add-on treatment for moderate-to-severe asthma – Sanofi + Regeneron

The FDA has approved Dupixent (dupilumab), from Sanofi + Regeneron, as an add-on maintenance treatment of patients aged 6 to 11 years with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid-dependent asthma. The FDA approval is based on data from a Phase III randomized, double-blind, placebo-controlled trial that evaluated the efficacy and safety of Dupixent combined with […]

Scientists identify severe asthma species, show air pollutant as likely contributor

Asthma afflicts more than 300 million people worldwide. The most severe manifestation, known as non-Th2, or non-atopic childhood asthma, represents the majority of the cases, greater than 85%, particularly in low-income countries, according to Hyunok Choi, an associate professor at the Lehigh University College of Health. Yet, whether non-Th2 is a distinct disease (or endotype) or simply a unique set […]

Triple inhaler therapy for asthma appears to improve outcomes

Article written by Bruce Sylvester. Researchers report that, when compared with dual inhaler therapy for moderate to severe asthma, triple therapy for children aged 6 to 18 years and adults is significantly associated with fewer severe exacerbations and with modest improvements in asthma control. The investigators also reported no significant differences between therapies in quality of life or mortality outcomes. […]